Osteoporosis in men: epidemiology and treatment with denosumab

References

• National Osteoporosis FoundationAmerica’s Bone Health: The State of Osteoporosis and Low Bone Mass in Our NationWashington, DCNational Osteoporosis Foundation2002
   Google Scholar
• GullbergBJohnellOKanisJAWorld-wide projections for hip fractureOsteoporos Int1997754074139425497
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderDSambrookPNEismanJAMortality after all major types of osteoporotic fracture in men and women: an observational studyLancet1999353915687888210093980
   PubMed Web of Science ®Google Scholar
• BliucDNguyenNDMilchVENguyenTVEismanJACenterJRMortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and womenJAMA2009301551352119190316
   PubMed Web of Science ®Google Scholar
• KannegaardPNvan der MarkSEikenPAbrahamsenBExcess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survivalAge Ageing201039220320920075035
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• BonewaldLFJohnsonMLOsteocytes, mechanosensing and Wnt signalingBone200842460661518280232
   PubMed Web of Science ®Google Scholar
• KearnsAEKhoslaSKostenuikPJReceptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and diseaseEndocr Rev200829215519218057140
   PubMed Web of Science ®Google Scholar
• SeemanEUnresolved issues in osteoporosis in menRev Endocr Metab Disord200121456411704979
   PubMedGoogle Scholar
• SeemanEGrowth in bone mass and size – are racial and gender differences in bone mineral density more apparent than real?J Clin Endocrinol Metab1998835141414199589631
   PubMed Web of Science ®Google Scholar
• PreeceMAPanHRatcliffeSGAuxological aspects of male and female pubertyActa Paediatr Suppl199238311131458004
   PubMedGoogle Scholar
• SeemanESexual dimorphism in skeletal size, density, and strengthJ Clin Endocrinol Metab200186104576458411600506
   PubMed Web of Science ®Google Scholar
• RiggsBLMeltonLJRobbRAA population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and menJ Bone Miner Res200823220521417937534
   PubMed Web of Science ®Google Scholar
• FinkHAEwingSKEnsrudKEAssociation of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older menJ Clin Endocrinol Metab200691103908391516849417
   PubMed Web of Science ®Google Scholar
• AaronJEMakinsNBSagreiyaKThe microanatomy of trabecular bone loss in normal aging men and womenClin Orthop Relat Res19872152602713802645
   PubMed Web of Science ®Google Scholar
• KhoslaSRiggsBLAtkinsonEJEffects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessmentJ Bone Miner Res200621112413116355281
   PubMed Web of Science ®Google Scholar
• KhoslaSAminSOrwollEOsteoporosis in menEndocr Rev200829444146418451258
   PubMed Web of Science ®Google Scholar
• EbelingPRClinical practice. Osteoporosis in menN Engl J Med2008358141474148218385499
   PubMed Web of Science ®Google Scholar
• AdlerRAOsteoporosis in men: recent progressEndocrine2013441404623354727
   PubMed Web of Science ®Google Scholar
• International Society for Clinical DensitometryIndications for bone mineral density (BMD) testing Available from: http://www.iscd.org/documents/2013/07/2013-iscd-official-positions-adult.pdfAccessed August 26, 2013
   Google Scholar
• WattsNBAdlerRABilezikianJPOsteoporosis in men: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab20129761802182222675062
   PubMed Web of Science ®Google Scholar
• QaseemASnowVShekellePHopkinsRJrForcieaMAOwensDKScreening for osteoporosis in men: a clinical practice guideline from the American College of PhysiciansAnn Intern Med2008148968068418458281
   PubMed Web of Science ®Google Scholar
• RaoSSBudhwarNAshfaqueAOsteoporosis in menAm Fam Physician201082550350820822086
   PubMed Web of Science ®Google Scholar
• Dawson-HughesBHarrisSSKrallEADallalGEEffect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or olderN Engl J Med1997337106706769278463
   PubMed Web of Science ®Google Scholar
• Institute of MedicineDietary Reference Intakes for Calcium and Vitamin DWashington, DCThe National Academies Press2011
   Google Scholar
• Bischoff-FerrariHAGiovannucciEWillettWCDietrichTDawson-HughesBEstimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomesAm J Clin Nutr2006841182816825677
   PubMed Web of Science ®Google Scholar
• QaseemASnowVShekellePHopkinsRJrForcieaMAOwensDKPharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of PhysiciansAnn Intern Med2008149640441518794560
   PubMed Web of Science ®Google Scholar
• OrwollEEttingerMWeissSAlendronate for the treatment of osteoporosis in menN Engl J Med2000343960461010979796
   PubMed Web of Science ®Google Scholar
• SawkaAMPapaioannouAAdachiJDGafniAHanleyDAThabaneLDoes alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in womenBMC Musculoskelet Disord200563916008835
   PubMed Web of Science ®Google Scholar
• RingeJDFaberHFarahmandPDorstAEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year studyRheumatol Int200626542743116001181
   PubMed Web of Science ®Google Scholar
• SatoYIwamotoJKanokoTSatohKRisedronate sodium therapy for prevention of hip fracture in men 65 years or older after strokeArch Intern Med2005165151743174816087822
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollESWenderothDStonerKJEusebioRDelmasPDOnce-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter studyJ Bone Miner Res200924471972519049326
   PubMed Web of Science ®Google Scholar
• OrwollESMillerPDAdachiJDEfficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled studyJ Bone Miner Res201025102239225020499357
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• KaufmanJMOrwollEGoemaereSTeriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapyOsteoporos Int200516551051615322742
   PubMed Web of Science ®Google Scholar
• GallagherJCGenantHKCransGGVargasSJKregeJHTeriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fracturesJ Clin Endocrinol Metab20059031583158715613428
   PubMed Web of Science ®Google Scholar
• OrwollESScheeleWHPaulSThe effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosisJ Bone Miner Res200318191712510800
   PubMed Web of Science ®Google Scholar
• SubbiahVMadsenVSRaymondAKBenjaminRSLudwigJAOf mice and men: divergent risks of teriparatide-induced osteosarcomaOsteoporos Int20102161041104519597911
   PubMed Web of Science ®Google Scholar
• Prolia^®(denosumab) Full prescribing information medication guideThousand Oaks, CAAmgen Inc9102013
   Google Scholar
• SutjandraLRodriguezRDDoshiSPopulation pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosisClin Pharmacokinet2011501279380722087866
   PubMed Web of Science ®Google Scholar
• BlockGABoneHGFangLLeeEPadhiDA single-dose study of denosumab in patients with various degrees of renal impairmentJ Bone Miner Res20122771471147922461041
   PubMed Web of Science ®Google Scholar
• MillerPDBologneseMALewieckiEMEffect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• OrwollETeglbjærgCSLangdahlBLA randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityJ Clin Endocrinol Metab20129793161316922723310
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBTorizNHDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• OrwollESBinkleyNCLewieckiEMGruntmanisUFriesMADasicGEfficacy and safety of monthly ibandronate in men with low bone densityBone201046497097620060082
   PubMed Web of Science ®Google Scholar
• BrownJPRouxCTörringODiscontinuation and associated fracture incidence: analysis from the FREEDOM trialJ Bone Miner Res201328474675223109251
   PubMed Web of Science ®Google Scholar
• Prolia^®(denosumab) Risk Evaluation and Mitigation Strategy (REMS)Thousand Oaks, CA, USAAmgen Inc Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM214383.pdfAccessed September 10, 2013
   Google Scholar
• FreemantleNSatram-HoangATangETFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenOsteoporos Int201223131732621927922
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPImproved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profileRheumatol Int1192013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• HiligsmannMBoonenADirksenCDBen SedrineWReginsterJYCost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic womenExpert Rev Pharmacoecon Outcomes Res2013131192823402442
   PubMed Web of Science ®Google Scholar
• JönssonBStrömOEismanJACost-effectiveness of denosumab for the treatment of postmenopausal osteoporosisOsteoporos Int201122396798220936401
   PubMed Web of Science ®Google Scholar